NCT01920737View on ClinicalTrials.gov

"A Novel Pediatric-Inspired Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia"

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

August 7, 2013

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Leukemia
Interventions
DRUG

Daunorubicin

In the event of a shortage of daunorubicin, doxorubicin may be used as a substitute.

DRUG

Vincristine

DRUG

Prednisone

DRUG

PEG-Asparaginase

DRUG

Methotrexate

DRUG

6-MP (6-Mercaptopurine)

DRUG

Cyclophosphamide

DRUG

Cytarabine

DRUG

Leucovorin

DRUG

Dexamethasone

OTHER

Blood draw

DEVICE

CT/PET scans

PET or CT scan every 6 months for 3 years

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

27701

Duke University Medical Center, Durham

Unknown

Weill Cornell Medical Center, New York

Sponsors

Collaborators (2)

Shire
Duke University
All Listed Sponsors
collaborator

Shire

INDUSTRY

collaborator

Duke University

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

Lehigh Valley Health Network

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01920737 - "A Novel Pediatric-Inspired Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia" | Biotech Hunter | Biotech Hunter